Abivax reported strong phase 3 efficacy for obefazimod in ulcerative colitis, with a 40% placebo-adjusted increase in clinical remission rates. However, the company’s stock fell sharply after it disclosed that several patients on the high-dose regimen developed cancers. The mixed outcome raises uncertainty around the risk-benefit profile needed for potential partnering or acquisition interest. Abivax has been viewed by some as a takeover candidate, and oncology-style safety signals can materially affect timelines for clinical continuation and any future discussions. Investors will now focus on the nature of the reported malignancies, exposure-response considerations, and what additional safety characterization Abivax can provide as the program proceeds.